BTP Viewed As Glomerular Filtration Rate Marker
By LabMedica International staff writers Posted on 24 Apr 2018 |
Image: The N Latex Cystatin C Assay for the detection of decline in renal function (Photo courtesy of Siemens Healthcare).
Beta Trace Protein (BTP) is a promising marker of glomerular filtration rate (GFR) as it was reported to be increased in the serum of patients with renal disease. Some evidence suggests that it is more sensitive than creatinine (Cr) at detecting early changes in GFR.
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms